# US 2023/0272379 A1 · Improved rna editing method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272379 A1
- Document ID: US20230272379A1
- Status: Published application
- Kind: A1
- Application number: 18/015,054
- Filed: 2021-07-06
- Published: 2023-08-31
- Earliest claimed: 2020-07-06
- Assignees: Edigene Therapeutics (Beijing) Inc.
- Applicants: Edigene Therapeutics (Beijing ) Inc.
- Inventors: Pengfei YUAN; Zexuan YI; Nengyin LIU
- Web page: https://patentgrep.com/patent/US20230272379A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- C12N 2310/10: Type of nucleic acid
- C12N 2310/11: Antisense
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided is a method for editing a target RNA at a target residue position of a host cell. The method comprises introducing ADAR-recruiting RNA (arRNA) or a construct encoding the arRNA into a host cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to a target RNA; the target residue is located in a three-base motif comprising a 5′ nearest-neighbor residue (upstream residue) of the target residue in the target RNA, the target residue, and a 3′ nearest-neighbor residue (downstream residue) of the target residue in the target RNA, wherein the three-base motif is not UAG, and the complementary RNA sequence comprises a mismatch directly opposite to the upstream residue or the downstream residue in the target RNA. Further provided are arRNA for the method, an RNA obtained by the method, a host cell comprising the RNA, and use of the method in the treatment of a disease.

## Claims

### Claim 1

A method for editing target RNA at a target residue position in a host cell, which comprises introducing ADAR-recruiting RNA (arRNA) or a construct encoding the arRNA into a host cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to a target RNA; the target residue is located in a three-base motif comprising a 5′ nearest-neighbor residue (upstream residue) of the target residue in the target RNA, the target residue, and a 3′ nearest-neighbor residue (downstream residue) of the target residue in the target RNA, wherein the three-base motif is not UAG, and the complementary RNA sequence comprises a mismatch directly opposite to the upstream residue and/or the downstream residue in the target RNA.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the target residue is adenosine.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the upstream residue is selected from the group consisting of: G, A, and C.

### Claim 6

(canceled)

### Claim 7 (depends on 4)

The method according to claim 4, wherein the complementary RNA sequence comprises cytidine, adenosine or uridine directly opposite to the target adenosine in the target RNA.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the complementary RNA sequence further comprises one or more mismatches respectively opposite to a non-target adenosine in the target RNA.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the three-base motif is GAU, and the complementary RNA sequence comprises ACG, UCC, CCU or ACA opposite to the three-base motif, wherein the three-base motif is GAA, the complementary RNA sequence comprises UCA, CCG, CCC or UCG opposite to the three-base motif, wherein the three-base motif is GAC, the complementary RNA sequence comprises GCG or GCA opposite to the three-base motif, and/or wherein the three-base motif is GAG, the complementary RNA sequence comprises CCG, CCA, CCC, UCC or UCG opposite to the three-base motif.

### Claim at position 9

10-17. (canceled)

### Claim 18 (depends on 4)

The method according to claim 4, wherein the upstream residue in the three-base motif is G, and the base opposite to the upstream residue in the complementary RNA is G or A.

### Claim 19 (depends on 4)

The method according to claim 4, wherein the downstream residue in the three-base motif is strictly complementary to the opposite base in the complementary RNA.

### Claim 20 (depends on 4)

The method according to claim 4, wherein the arRNA recruits an adenosine deaminase acting on RNA (ADAR) or a fusion protein comprising an ADAR catalytic domain to deaminate the target adenosine in the target RNA, and wherein the ADAR protein or the fusion protein comprising an ADAR catalytic domain, or a construct encoding the ADAR protein or the fusion protein comprising an ADAR catalytic domain is exogenously introduced into the host cell, or the ADAR protein is endogenously expressed by the host cell.

### Claim at position 13

21-23. (canceled)

### Claim 24 (depends on 1)

The method according to claim 1, wherein the target residue is cytidine, and the arRNA recruits a deaminase acting on RNA and having cytidine deaminase activity to deaminate the target cytidine in the target RNA.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the three-base motif in which the target cytidine in the target RNA is located is any one selected from the group consisting of: GCG, GCC, GCA, GCU, ACG, ACC, ACA, ACU, CCG, CCC, CCA, CCU, UCA, UCC, UCU, and UCG.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the complementary RNA sequence comprises cytidine, adenosine or uridine opposite to the target cytidine in the target RNA.

### Claim 27 (depends on 24)

The method according to claim 24, wherein the complementary RNA sequence further comprises one or more mismatches respectively opposite to a non-target cytidine in the target RNA.

### Claim 28 (depends on 24)

The method according to claim 24, wherein the upstream residue in the three-base motif is G, and the base opposite to the upstream residue in the complementary RNA is G.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the three-base motif is GCA, and the complementary RNA sequence comprises UUG or UCG opposite to the three-base motif, and/or wherein the three-base motif is CCA, the complementary RNA sequence comprises AUG opposite to the three-base motif.

### Claim at position 20

30-32. (canceled)

### Claim 33 (depends on 24)

The method according to claim 24, wherein the deaminase with the cytidine deaminase activity is a deaminase with the C-to-U catalytic activity obtained by gene modification of ADAR protein or a fusion protein comprising an ADAR catalytic domain.

### Claim at position 22

34-45. (canceled)

### Claim 46 (depends on 1)

The method according to claim 1, wherein the host cell is a eukaryocyte.

### Claim at position 24

47-50. (canceled)

### Claim 51 (depends on 1)

A method for treating or preventing a disease or condition in an individual, comprising editing a target RNA associated with the disease or condition in cells of the individual by the method according to claim 1.

### Claim 52

(canceled)

### Claim 53 (depends on 1)

An arRNA used in the method according to claim 1.

### Claim 54

(canceled)

### Claim 55 (depends on 53)

A library, comprising a plurality of arRNAs according to claim 53.

### Claim at position 30

56-57. (canceled)
